Halozyme (HALO) Announces 6.8M Common Offering
Down)
Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced that it is offering to sell 6,800,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Barclays Capital Inc. is the sole book-running manager of the offering, and Halozyme intends to grant them a thirty (30) day option to purchase up to an additional 1,020,000 shares of common stock. All of the shares in the offering are to be sold by Halozyme. Halozyme intends to use the net proceeds from the offering to build commercial inventory for anticipated product launches, fund research and development of proprietary programs, and for general corporate purposes.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Peoples Bancorp (PEBO) Files $100M Mixed Shelf
- Rossetta Genomics (ROSG) Sells 570K Shares at $11.50/Sh
- Uni-Pixel (INXL) Files $50M Mixed Shelf; 2.46M Common for Selling Shareholders
Create E-mail Alert Related Categories
Equity OfferingsRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
